For validation experiments, we employed distinct SHH-subtype medulloblastoma (SMB) in vitro models derived from Ptch+/- mice [65], previously shown to uniformly recapitulate SHH-MB hallmark features, as well as cell line derivates of one of those models that incorporate genetic alterations associated with SMO inhibitor resistance [64, 65]. The gene discussed is SMO; the disease is medulloblastoma.